Kenneth Pittman
Contributor since: 2014
Company: Private medical office
Articles
MEI Pharma: Time To Reload At Key Support Level
Supernus Is Once Again A Super Value
Strength From Muscle Biology With Cytokinetics
Neuroscience In Big Pharma: Eli Lilly
Attention With KP-415 Is Better Than The Market's Attention On KemPharm
ADHD Check-Up: Which Future Medications Have The Greatest Potential?
Dynavax: 2 Mg Vs. 8 Mg Response Is Not The 'Kiss Of Death'
GW Pharmaceuticals: Value Beyond Epidiolex?
Aevi Genomic Medicine: Try Subgroups Until It Works?
Zynerba: Transdermal Cannabinoids Have Significant Potential
KemPharm: Patients Not Liking Their Drugs Is Great News
Tonix: PTSD Breakthrough Or Too Risky For Stockholders?
How To Play 'Am I Diversified?' In The Pharma/Biotech Space
The Takeda-Shire Deal: Potential Impact On Neuroscience
Will Butterflies Or Moths Emerge From Ovid's Cocoons?
Supernus Is Worth A Super-Sized Portfolio Position
Acadia: Will Nuplazid Become More Than A One-Trick Pony?
Minerva: Get Ahead Of The Rush?
Cytokinetics: Multiple Catalysts Could Help With Rebound
Axsome: Potentially More Pain Than Gain
Alkermes: A Solid CNS Portfolio With An Option For Depression
Marinus Pharma's Ganaxolone: If At First You Don't Succeed...
Update: Neos Therapeutics Seems To Be Capitalizing On Pfizer's Decisions
Does Sage's Antidepressant Franchise Make It An Acquisition Target?
VistaGen: Risky Anti-Depression Play
Esketamine Could Give Johnson & Johnson The Next Major Psych Blockbuster
Is Allergan The Best Buy If You (Or Your Portfolio) Are Depressed?
Shire Should Spin Off Neuroscience And Make A Deal With Supernus
Ignore The Pain And Get A (Portfolio) Stimulant With KemPharm
NEOS Is Poised To Take Advantage Of Missteps By Pfizer And Noven
Is Redhill Worth Our Green Bills?
Can Pharma Succeed In A Condition Impacting 1 In 68 Children?